D. E. Shaw & Co., Inc. Savara Inc Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Savara Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 70,560 shares of SVRA stock, worth $198,979. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70,560
Previous 17,013
314.74%
Holding current value
$198,979
Previous $72,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SVRA
# of Institutions
140Shares Held
158MCall Options Held
55.6KPut Options Held
600-
Nea Management Company, LLC Timonium, MD24.5MShares$69 Million5.37% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$41.1 Million12.07% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$34.9 Million6.2% of portfolio
-
Vestal Point Capital, LP New York, NY10.8MShares$30.4 Million1.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.66MShares$24.4 Million1.59% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $322M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.